Markets
Karyopharm Endometrial Cancer Trial Fails: What the Clinical Miss Means for KPTI Stock
Karyopharm Therapeutics' Phase 3 trial in endometrial cancer failed to hit its primary endpoint, sending the biotech's shares into sharp retreat and raising hard questions about the company's pipeline diversification strategy.